Protocol
Autologous stem cell therapy
Adipose-derived stem cells · ADSC · Autologous MSC · Mesenchymal stem cell therapy · Adipose tissue-derived stem cell therapy
There is no human randomised controlled trial showing that autologous adipose-derived stem cell therapy extends healthspan, slows biological ageing, or improves any validated ageing outcome. The trial literature that clinics gesture at is largely in different products and different indications: allogeneic (donor) mesenchymal cell infusions studied in small early-phase frailty trials, and autologous cell injections studied for localised joint and wound repair. Neither supports a systemic rejuvenation claim, and allogeneic frailty data cannot be transferred to an autologous adipose product. What is genuinely established is mechanism (MSCs are immunomodulatory and paracrine-active) plus a commercial market. Claims spanning dozens of unrelated conditions, as seen on clinic pages, are a marker of weak evidence rather than broad efficacy. Known risks include liposuction harvest complications, injection-site events, and, for unregulated preparations, contamination and inappropriate cell differentiation. Graded commercial: it is sold and marketed well ahead of the evidence.
At a glance
- Evidence
- Commercial
- Singapore (HSA)
- No HSA-registered stem cell product for an anti-ageing or longevity indication was found, so there is no approved longevity use in Singapore. HSA regulates stem cell products as Cell, Tissue and Gene Therapy Products (CTGTP) under the Health Products (CTGTP) Regulations 2021, split into Class 1 (minimally manipulated, homologous use, not combined with a therapeutic product or device) and Class 2 (everything else, including culture-expanded cells, which requires full registration). Separately, cells taken from a patient, minimally manipulated, and reimplanted into the same patient for homologous use within the same surgical procedure fall outside CTGTP regulation entirely and sit under the Healthcare Services Act. Which of these applies to a given clinic offering depends on facts the clinic does not publish (degree of manipulation, culture expansion, and where processing occurs). Material caveat: the Artisan Regenerative Centre page does not state whether cells are processed and administered in Singapore or offshore, and culture expansion for a non-homologous systemic anti-ageing purpose would fall into Class 2 and require registration. Status for longevity use: not approved, and the regulatory pathway for any specific offering is unverified.
- Australia (TGA)
- Not TGA-approved for any longevity or anti-ageing indication. Autologous human cell and tissue (HCT) products are excluded from TGA regulation only in a narrow case: collected from a patient under a medical or dental practitioner's clinical care, manufactured by or under that practitioner's supervision, and used in an accredited hospital for that same patient. Outside that carve-out they fall under the Biologicals Regulatory Framework, with reduced requirements for minimally manipulated homologous use and the full framework for more than minimally manipulated or non-homologous use, which is what a systemic anti-ageing application would be. Critically, direct-to-consumer advertising of these products is prohibited, mirroring the ban on advertising prescription medicines, although clinics may advertise services without naming the product. This is why no Australian clinic in the target list markets stem cell therapy, and it means absence from Australian clinic websites cannot be read as absence of practice. SOURCING LIMITATION, must be re-verified before publication: tga.gov.au returned repeated 60 second timeouts across five separate fetch attempts in this session (practitioner guidance, HCT overview, stem cell advertising guidance, and the framework PDF). The characterisation above is sourced from MIPS, an Australian medical indemnity body summarising the TGA position, not from a TGA primary page opened live. Do not publish this regulatory claim until confirmed directly against tga.gov.au.
- Offered at
- 1 clinic
Singapore
Health Sciences Authority
- HSA status
- No HSA-registered stem cell product for an anti-ageing or longevity indication was found, so there is no approved longevity use in Singapore. HSA regulates stem cell products as Cell, Tissue and Gene Therapy Products (CTGTP) under the Health Products (CTGTP) Regulations 2021, split into Class 1 (minimally manipulated, homologous use, not combined with a therapeutic product or device) and Class 2 (everything else, including culture-expanded cells, which requires full registration). Separately, cells taken from a patient, minimally manipulated, and reimplanted into the same patient for homologous use within the same surgical procedure fall outside CTGTP regulation entirely and sit under the Healthcare Services Act. Which of these applies to a given clinic offering depends on facts the clinic does not publish (degree of manipulation, culture expansion, and where processing occurs). Material caveat: the Artisan Regenerative Centre page does not state whether cells are processed and administered in Singapore or offshore, and culture expansion for a non-homologous systemic anti-ageing purpose would fall into Class 2 and require registration. Status for longevity use: not approved, and the regulatory pathway for any specific offering is unverified.
- In our SG set
- Tracked in Singapore
- SG clinics
- 1
Australia
Therapeutic Goods Administration
- TGA status
- Not TGA-approved for any longevity or anti-ageing indication. Autologous human cell and tissue (HCT) products are excluded from TGA regulation only in a narrow case: collected from a patient under a medical or dental practitioner's clinical care, manufactured by or under that practitioner's supervision, and used in an accredited hospital for that same patient. Outside that carve-out they fall under the Biologicals Regulatory Framework, with reduced requirements for minimally manipulated homologous use and the full framework for more than minimally manipulated or non-homologous use, which is what a systemic anti-ageing application would be. Critically, direct-to-consumer advertising of these products is prohibited, mirroring the ban on advertising prescription medicines, although clinics may advertise services without naming the product. This is why no Australian clinic in the target list markets stem cell therapy, and it means absence from Australian clinic websites cannot be read as absence of practice. SOURCING LIMITATION, must be re-verified before publication: tga.gov.au returned repeated 60 second timeouts across five separate fetch attempts in this session (practitioner guidance, HCT overview, stem cell advertising guidance, and the framework PDF). The characterisation above is sourced from MIPS, an Australian medical indemnity body summarising the TGA position, not from a TGA primary page opened live. Do not publish this regulatory claim until confirmed directly against tga.gov.au.
- In our AU set
- Not tracked in Australia
- AU clinics
- None on file
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.
What it is
Plain-language explainer
Autologous stem cell therapy takes a patient's own cells, most commonly mesenchymal stromal cells isolated from fat harvested by liposuction (adipose-derived stem cells), processes them, and returns them to the same patient by injection or infusion. In longevity clinics it is marketed on the claim that reintroduced stem cells repair damaged tissue and replenish aged tissue throughout the body. That systemic anti-ageing framing is a clinic claim, not a regulator-approved indication, and it is distinct from the narrow orthopaedic and haematological settings where cell therapy has an established role.
Categories
Protocol
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Cell, Tissue and Gene Therapy Products: Regulatory Overview · Health Sciences Authority (HSA), Singapore
- Stem Cell Therapy · Artisan Regenerative Centre, Singapore
- TGA Regulation of Autologous Human Cell and Tissue Products · MIPS (Medical Indemnity Protection Society), Australia
Every entity profile on variis is sourced. Not medical advice.